SAN

73.48

-0.82%↓

ARGX

691.8

-3.19%↓

SHL.DE

34.13

-0.35%↓

PHIA

22.12

-1.12%↓

FRE

36.49

+2.67%↑

SAN

73.48

-0.82%↓

ARGX

691.8

-3.19%↓

SHL.DE

34.13

-0.35%↓

PHIA

22.12

-1.12%↓

FRE

36.49

+2.67%↑

SAN

73.48

-0.82%↓

ARGX

691.8

-3.19%↓

SHL.DE

34.13

-0.35%↓

PHIA

22.12

-1.12%↓

FRE

36.49

+2.67%↑

SAN

73.48

-0.82%↓

ARGX

691.8

-3.19%↓

SHL.DE

34.13

-0.35%↓

PHIA

22.12

-1.12%↓

FRE

36.49

+2.67%↑

SAN

73.48

-0.82%↓

ARGX

691.8

-3.19%↓

SHL.DE

34.13

-0.35%↓

PHIA

22.12

-1.12%↓

FRE

36.49

+2.67%↑

Strona główna・Stock List・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

57.8 -0.86

Buy Sell

Overview

Share price change

24h

Current

Min

57.6

Max

58.7

Key metrics
By Trading Economics
Income	-33M 9.5M
Sales	-66M 152M
P/E Sector Avg	25.593 50.102
EPS	0.185
Profit margin	6.216
Employees	1,950
EBITDA	-45M 18M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+24.11% upside

Dividends
By Dow Jones
Next Earnings	23 lip 2026

Market Stats
By TradingEconomics
Market Cap	-972M 3.1B
Previous open	58.66
Previous close	57.8

News Sentiment

By Acuity

50%

153 / 344 Ranking in Healthcare

Laboratorios Farmaceuticos Rovi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 cze 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 cze 2026, 23:38 UTC

Acquisitions, Mergers, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 cze 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 cze 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 cze 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 cze 2026, 22:08 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 cze 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 cze 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 cze 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 cze 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 cze 2026, 21:22 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 cze 2026, 20:46 UTC

Acquisitions, Mergers, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 cze 2026, 20:22 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 cze 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 cze 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 cze 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 cze 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 cze 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 cze 2026, 18:54 UTC

Acquisitions, Mergers, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 cze 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 cze 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 cze 2026, 18:00 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 cze 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 cze 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 cze 2026, 17:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

24.11% upside

12 Months Forecast

Average 73.6 EUR 24.11%

High 83 EUR

Low 64.2 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Laboratorios Farmaceuticos Rovi SA - Dist in the past 3 months.

Sentiment

By Acuity

153 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.